Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 43 citing articles:

PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
Adil Parvez, Furqan Choudhary, Priyal Mudgal, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 57
Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges
Sadique A. Javed, Asim Najmi, Waquar Ahsan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 18
Malaria: Factors affecting disease severity, immune evasion mechanisms, and reversal of immune inhibition to enhance vaccine efficacy
Xin‐zhuan Su, Fangzheng Xu, Rachel V. Stadler, et al.
PLoS Pathogens (2025) Vol. 21, Iss. 1, pp. e1012853-e1012853
Open Access | Times Cited: 1
Small molecule agents for triple negative breast cancer: Current status and future prospects
Yan Ou, Mengchao Wang, Qian Xu, et al.
Translational Oncology (2024) Vol. 41, pp. 101893-101893
Open Access | Times Cited: 12
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Natalie Fuchs, Longfei Zhang, Laura Calvo‐Barreiro, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 68-68
Open Access | Times Cited: 8
Identification of a small-molecule Tim-3 inhibitor to potentiate T cell–mediated antitumor immunotherapy in preclinical mouse models
Shuaiya Ma, Ye Tian, Jiali Peng, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 722
Closed Access | Times Cited: 19
Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
Shizuko Sei, Aysel Ahadova, Derin B. Keskin, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 16
The BTLA-HVEM complex – The future of cancer immunotherapy
Karolina Wojciechowicz, Marta Spodzieja, Anna Wardowska
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116231-116231
Open Access | Times Cited: 6
Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade
Eun‐Ji Lee, Young Soo Kim, Ji Hye Kim, et al.
Phytomedicine (2024) Vol. 125, pp. 155370-155370
Open Access | Times Cited: 5
Research Progress in Bifunctional small molecules for cancer immunotherapy
Binbin Cheng, Hongqiao Li, Yun Hong, et al.
European Journal of Medicinal Chemistry (2025) Vol. 286, pp. 117289-117289
Closed Access
Advancements in drug discovery: integrating CADD tools and drug repurposing for PD-1/PD-L1 axis inhibition
Patrícia Sobral, T. Carvalho, Shiva Izadi, et al.
RSC Advances (2025) Vol. 15, Iss. 4, pp. 2298-2316
Open Access
Enhancing immunity during ageing by targeting interactions within the tissue environment
Olivia V. Bracken, Roel P. H. De Maeyer, Arne N. Akbar
Nature Reviews Drug Discovery (2025)
Closed Access
Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 4
A Comprehensive Computational Insight into the PD-L1 Binding to PD-1 and Small Molecules
Marialuigia Fantacuzzi, Roberto Paciotti, Mariangela Agamennone
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 316-316
Open Access | Times Cited: 4
Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma
Somaya A. Abdel‐Rahman, Moustafa T. Gabr
Cancers (2024) Vol. 16, Iss. 2, pp. 435-435
Open Access | Times Cited: 3
Exploring the Surface of the Ectodomain of the PD-L1 Immune Checkpoint with Small-Molecule Fragments
Radosław Kitel, Ismael Rodríguez, Xabier del Corte, et al.
ACS Chemical Biology (2022) Vol. 17, Iss. 9, pp. 2655-2663
Open Access | Times Cited: 14
Discovery of bioactive natural products of microbial origin as inhibitors of the PD-1/PD-L1 protein-protein interaction
Elisabeth Domingo-Contreras, José R. Tormo, Víctor González-Menéndez, et al.
International Journal of Biological Macromolecules (2024) Vol. 264, pp. 130458-130458
Closed Access | Times Cited: 1
Structural Insights of PD-1/PD-L1 Axis: An In silico Approach
Shishir Rohit, Mehul Patel, Yogesh Jagtap, et al.
Current Protein and Peptide Science (2024) Vol. 25, Iss. 8, pp. 638-650
Closed Access | Times Cited: 1
Ring Transformation of Cyclopropenes to Benzo‐Fused Five‐Membered Oxa‐ and Aza‐Heterocycles via a Formal [4+1] Cyclization
Fengyan Gu, Binyan Lin, Zhi‐Huan Peng, et al.
Advanced Science (2024) Vol. 11, Iss. 40
Open Access | Times Cited: 1
Small molecules from antibody pharmacophores (SMAbPs) as a hit identification workflow for immune checkpoints
Somaya A. Abdel‐Rahman, Moustafa T. Gabr
Science Advances (2024) Vol. 10, Iss. 42
Open Access | Times Cited: 1
Deciphering LAG-3: unveiling molecular mechanisms and clinical advancements
Alejandra Martínez‐Pérez, Rocío Granda‐Díaz, Candelaria Aguilar-García, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 1
Comprehensive Advanced Physicochemical Characterization and In Vitro Human Cell Culture Assessment of BMS-202: A Novel Inhibitor of Programmed Cell Death Ligand
Hasham S. Sofi, Andrea J. Lora, Haley M. Donow, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1409-1409
Open Access | Times Cited: 1
Revolutionizing Cancer Immunotherapy: Emerging Nanotechnology-Driven Drug Delivery Systems for Enhanced Therapeutic Efficacy
Theivendren Panneerselvam, Selvaraj Kunjiappan, Parasuraman Pavadai, et al.
ACS Measurement Science Au (2024) Vol. 5, Iss. 1, pp. 31-55
Open Access | Times Cited: 1
A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition
Xavier Thuru, Romain Magnez, Gérard Vergoten, et al.
Biomedicine Hub (2023) Vol. 8, Iss. 1, pp. 1-9
Open Access | Times Cited: 4
Bis(benzonitrile) dichloroplatinum (II) interrupts PD-1/PD-L1 interaction by binding to PD-1
Rui-na Wang, Qian Yu, Xiaobo Wang, et al.
Acta Pharmacologica Sinica (2023) Vol. 44, Iss. 10, pp. 2103-2112
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top